10 Einträge von 145 mit factor vitamin
www.cslbehring.ch
Datum der Indexierung 21.01.2024 21:23:06
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
www.cslbehring.ch
Datum der Indexierung 15.01.2024 02:32:16
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
www.cslbehring.ch
Datum der Indexierung 10.01.2024 05:07:55
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
www.cslbehring.ch
Datum der Indexierung 15.01.2024 02:34:08
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759
www.cslbehring.ch
Datum der Indexierung 10.01.2024 05:09:40
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759
www.cslbehring.ch
Datum der Indexierung 15.01.2024 02:34:58
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 10.01.2024 05:10:09
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 21.01.2024 21:25:21
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759
www.cslbehring.ch
Datum der Indexierung 21.01.2024 21:25:55
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 21.01.2024 21:20:17
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies news | with patients | behring mehr | that through | disease support | products factor | initiated high | clinical research | investigator quality | application including |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036325
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies news | with patients | behring mehr | that through | disease support | products factor | initiated high | clinical research | investigator quality | application including |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036325